CDSCO Panel grants Novartis Protocol Amendment proposal for Remibrutinib study in Relapsing Multiple Sclerosis Dr. Divya Colin5 Feb 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
CDSCO Panel Grants Novartis Protocol Amendment For Ofatumumab Dr. Divya Colin31 Dec 2023 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
Roche gets CDCSO panel nod to market multiple sclerosis drug Ocrelizumab Dr. Divya Colin26 Jan 2023 6:00 PM ISTNew Delhi: Pharmaceutical major, Roche has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Control...
Merck completes enrolment of Evobrutinib Phase III Trials ahead of ECTRIMS 2021 Ruchika Sharma5 Oct 2021 10:00 AM ISTDarmstadt: Merck, a science and technology company, has recently announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial...
Janssen gets positive CHMP opinion for Ponvory for treating relapsing forms of multiple sclerosis in adults Ruchika Sharma29 March 2021 10:00 AM ISTBelgium: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Medicines Agency's (EMA) Committee for...
Janssen Pharma gets USFDA nod for Ponvory to treat relapsing multiple sclerosis Ruchika Sharma21 March 2021 10:15 AM ISTNew Jersy: The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (USFDA) approved PONVORY...
